Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Hansoh Pharmaceutical Group Co's EV-to-FCF or its related term are showing as below:
HKSE:03692'
s EV-to-FCF Range Over the Past 10 Years
Min: 13.81 Med: 31.67 Max: 222.6
Current: 21.34
During the past 11 years, the highest EV-to-FCF of Hansoh Pharmaceutical Group Co was 222.60. The lowest was 13.81. And the median was 31.67.
HKSE:03692's EV-to-FCF is ranked worse than 52.27% of 572
companies
in the Drug Manufacturers industry
Industry Median: 18.89
vs HKSE:03692: 21.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hansoh Pharmaceutical Group Co (HKSE:03692) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hansoh Pharmaceutical Group Co's PE Ratio (TTM) for today is calculated as:
Hansoh Pharmaceutical Group Co's share price for today is HK$35.32.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hansoh Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was HK$1.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hansoh Pharmaceutical Group Co EV-to-FCF Related Terms
Hansoh Pharmaceutical Group Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's EV-to-FCF falls into.
Hansoh Pharmaceutical Group Co's current Enterprise Value is HK$177,377 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hansoh Pharmaceutical Group Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was HK$4,199 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co (HKSE:03692) has a EV-to-FCF of 42.25 as of Sep. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hansoh Pharmaceutical Group Co and its competitors. This is 33% above median its historical median of 31.67. Over the past decade, Hansoh Pharmaceutical Group Co's EV-to-FCF has ranged from 13.81 to 222.60. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #299 out of 572 companies in the Drug Manufacturers industry, placing it in the top 52.3%.
Is Hansoh Pharmaceutical Group Co's EV-to-FCF too high?
Hansoh Pharmaceutical Group Co's current EV-to-FCF of 42.25 is 33% above median its 10-year median of 31.67. Over the past 10 years, this metric has ranged from a low of 13.81 to a high of 222.60. The Drug Manufacturers industry median EV-to-FCF is 18.89. Hansoh Pharmaceutical Group Co's value of 42.25 is 123.7% above this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #299 out of 572 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #299 out of 572 companies for EV-to-FCF. This places Hansoh Pharmaceutical Group Co in the lower half of its industry. The industry median EV-to-FCF is 18.89. Hansoh Pharmaceutical Group Co's value of 42.25 is 123.7% above this benchmark. Historically, Hansoh Pharmaceutical Group Co's own EV-to-FCF has ranged from 13.81 to 222.60 over the past decade. While the company's 10-year median is 31.67 vs. the industry median of 18.89, Hansoh Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 18.89, based on 572 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current EV-to-FCF of 42.25 is 123.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Hansoh Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 18.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current EV-to-FCF is 42.25, which is 33% above median its own 10-year median of 31.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HKSE:03692) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$27.66, compared to a current price of HK$35.32 — trading 27.7% above its estimated fair value. The current EV-to-FCF is 42.25, which is 33% above median its 10-year median of 31.67 and 123.7% above the Drug Manufacturers industry median of 18.89. Hansoh Pharmaceutical Group Co's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HKSE:03692), the current EV-to-FCF is 42.25 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HKSE:03692) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of HK$35.32 is trading 27.7% above its estimated GF Value™ of HK$27.66.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for HKSE:03692:
EV-to-FCF: 42.25 (33% above median its 10-year median of 31.67)
GF Value™: HK$27.66 vs. price of HK$35.32 (27.7% above fair value)
Industry Position: 123.7% above the Drug Manufacturers median (#299 of 572)
No single metric tells the full story. See the HKSE:03692 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
91GF Score
Get the complete analysis for HKSE:03692
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03692 has been successfully added to your 
